David Buck
Stock Analyst at B. Riley Securities
(0.26)
# 4,065
Out of 4,820 analysts
14
Total ratings
21.43%
Success rate
-27.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Buck
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNOV MediciNova | Assumes: Buy | $22 | $1.56 | +1,310.26% | 2 | Mar 25, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $68 → $65 | $32.28 | +101.36% | 3 | Nov 12, 2018 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $219 → $190 | $113.06 | +68.05% | 4 | Nov 8, 2018 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $26 → $28 | $7.63 | +267.21% | 2 | Aug 22, 2018 | |
| ALKS Alkermes | Initiates: Buy | $60 | $27.91 | +114.98% | 1 | Jun 6, 2018 | |
| EVOK Evoke Pharma | Reinstates: Buy | $1,440 | $2.60 | +55,284.62% | 2 | Oct 19, 2017 |
MediciNova
Mar 25, 2019
Assumes: Buy
Price Target: $22
Current: $1.56
Upside: +1,310.26%
Supernus Pharmaceuticals
Nov 12, 2018
Maintains: Buy
Price Target: $68 → $65
Current: $32.28
Upside: +101.36%
Jazz Pharmaceuticals
Nov 8, 2018
Maintains: Buy
Price Target: $219 → $190
Current: $113.06
Upside: +68.05%
Amneal Pharmaceuticals
Aug 22, 2018
Maintains: Buy
Price Target: $26 → $28
Current: $7.63
Upside: +267.21%
Alkermes
Jun 6, 2018
Initiates: Buy
Price Target: $60
Current: $27.91
Upside: +114.98%
Evoke Pharma
Oct 19, 2017
Reinstates: Buy
Price Target: $1,440
Current: $2.60
Upside: +55,284.62%